ES2829637T3 - 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné - Google Patents

3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné Download PDF

Info

Publication number
ES2829637T3
ES2829637T3 ES15816887T ES15816887T ES2829637T3 ES 2829637 T3 ES2829637 T3 ES 2829637T3 ES 15816887 T ES15816887 T ES 15816887T ES 15816887 T ES15816887 T ES 15816887T ES 2829637 T3 ES2829637 T3 ES 2829637T3
Authority
ES
Spain
Prior art keywords
compound
dihydroxy
stilbene
isopropyl
acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15816887T
Other languages
English (en)
Spanish (es)
Inventor
Javier Cote-Sierra
Susan H Smith
Steven M Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Application granted granted Critical
Publication of ES2829637T3 publication Critical patent/ES2829637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15816887T 2014-12-12 2015-12-09 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné Active ES2829637T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Publications (1)

Publication Number Publication Date
ES2829637T3 true ES2829637T3 (es) 2021-06-01

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15816887T Active ES2829637T3 (es) 2014-12-12 2015-12-09 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné

Country Status (11)

Country Link
US (1) US10376475B2 (enExample)
EP (1) EP3229840B1 (enExample)
JP (3) JP7313117B2 (enExample)
KR (1) KR102607222B1 (enExample)
AR (1) AR102973A1 (enExample)
AU (1) AU2015358910B2 (enExample)
CA (1) CA2970739C (enExample)
DK (1) DK3229840T5 (enExample)
ES (1) ES2829637T3 (enExample)
TW (1) TWI692357B (enExample)
WO (1) WO2016092493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
IL316851A (en) 2015-05-21 2025-01-01 Dermavant Sciences GmbH Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
CA3082115A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
WO2020174467A1 (en) * 2019-02-25 2020-09-03 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof- tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
WO2021014453A1 (en) * 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4061332A4 (en) * 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
JP2025529076A (ja) * 2022-08-30 2025-09-04 ダーマヴァント サイエンシーズ ゲーエムベーハー ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
ATE444960T1 (de) 1999-12-06 2009-10-15 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
AU2003271470B2 (en) * 2002-10-01 2010-03-18 Welichem Biotech Inc. Novel bioactive diphenyl ethene compounds and their therapeutic applications
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
WO2009108762A2 (en) * 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
BR112013033617B1 (pt) * 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17

Also Published As

Publication number Publication date
JP7313117B2 (ja) 2023-07-24
DK3229840T5 (da) 2020-11-16
TWI692357B (zh) 2020-05-01
JP2023123554A (ja) 2023-09-05
JP2021152018A (ja) 2021-09-30
TW201639548A (zh) 2016-11-16
KR20170095928A (ko) 2017-08-23
KR102607222B1 (ko) 2023-11-29
US10376475B2 (en) 2019-08-13
EP3229840B1 (en) 2020-09-09
AU2015358910A1 (en) 2017-06-29
AU2015358910B2 (en) 2019-01-24
WO2016092493A1 (en) 2016-06-16
US20170360719A1 (en) 2017-12-21
DK3229840T3 (da) 2020-11-09
EP3229840A1 (en) 2017-10-18
CA2970739A1 (en) 2016-06-16
AR102973A1 (es) 2017-04-05
JP2017537936A (ja) 2017-12-21
CA2970739C (en) 2023-10-03

Similar Documents

Publication Publication Date Title
AU2015358910B2 (en) Novel method of use
JP6944399B2 (ja) プロバイオティクス細菌
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
US20230165915A1 (en) Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US20150017227A1 (en) Methods and Compositions for Treating Skin Diseases and Conditions
KR20100016450A (ko) 피부 외용제 조성물
JP2017082019A (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
CN102256608A (zh) 含有血单核细胞培养物的上清液的药物制剂
RU2687151C2 (ru) Тетрапептиды, полученные из с-х-с-хемокинов человека, подходящие для лечения различных состояний кожи
CN114080230A (zh) 氧化低渗酸溶液的治疗用途
US20250152647A1 (en) Formulations and methods for skin care
Chen et al. Effects of rhynchophylline and isorhynchophylline on nitric oxide and endothelin-1 secretion from RIMECs induced by Listeriolysin O in vitro
Khodaie et al. Impact of mummy substance on the proliferation and migration of human adipose-derived stem cells and fibroblasts in separate or co-culture model
TW201711696A (zh) 用於促進傷口癒合的吳郭魚抗菌胜肽
RU2822544C2 (ru) Терапевтическое применение окислительных гипотонических кислотных растворов
Liu et al. 1, 25-Dihydroxyvitamin D3 attenuates TGF-β1-induced airway remodeling in asthma by inhibiting IL-33 mediated by the ERK1/2 signaling pathway
Arnke The role of MIF-2 in obesity-induced wound healing disorder
Urata et al. 962 Administration of IL-31 induces anxiety-like behavior in mice
Tomii et al. 965 The importance of CD206+ macrophages in squaric acid dibutylester-induced hair cycle activation
Aldehalan et al. 960 A metabolite produced by skin commensal bacteria enhances epithelial integrity in human keratinocyte
Dinic et al. 961 Opportunist turns pathogen: Multidrug resistant Staphylococcus epidermidis is associated with the wound chronicity
Kosaka et al. 963 Linear ubiquitin chain assembly complex (LUBAC) is involved in the development of murine imiquimod (IMQ)-induced and IL-23-induced psoriasis models
CN121370715A (zh) 一种用于延缓细胞衰老、维持组织稳态的组合物及其制备方法和应用
Dastjerdi Co-regulation of the Cytochrome P450 24A1 Gene in a Model of Kidney Fibrosis by 1, 25 Dihydroxyvitamin D3 and Growth Factors
Hsieh et al. Novel regulation of hypertrophic scar remodeling by ON101 cream through SMAD2/CTGF inhibition in fibroblast–organoid systems